3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
4
Neutropenia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Early Stage Breast Cancer
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Hodgkin Disease
1
Graft vs Host Disease
1
Febrile Neutropenia
1
Interventions
Filgrastim
2
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Early Stage Breast Cancer
×
Filgrastim
×
Clear all
NCT02816112
2020-05-27
REaCT-TC2
Ottawa Hospital Research Institute
Phase 4
Completed
458 enrolled
NCT02816164
2019-09-06
REaCT-G2
Ottawa Hospital Research Institute
Phase 4
Completed
324 enrolled